Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celularity Inc. (CELU) on June 30, 2026, covering events occurring on June 26 and June 29, 2026. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Obligations
The filing discloses a new secured loan agreement rather than standard periodic financial results. Key terms include:
- Principal Amount: $1,000,000
- Lender: Philip & Daniele Barach Family Trust (affiliated with a beneficial owner of >5% of Class A common stock)
- Interest Rate: 4.0% per annum, increasing to 18.0% per annum upon an event of default at the Lender's election
- Maturity: The earlier of 30 days after closing or the Company's receipt of gross proceeds from certain financing or strategic transactions
- Collateral: First-priority security interest in substantially all personal property, subject to existing liens held by Helena Global Investment Opportunities 1 Ltd.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity positions outside of this specific transaction.
Material Changes and Corporate Governance
Effective June 26, 2026, Vincent LeVien resigned as a member of the Board of Directors. The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices. Additionally, the entry into the Loan Agreement constitutes a related person transaction under Item 404(a) of Regulation S-K.
Outlook, Risks, and Contingencies
The loan agreement contains customary covenants and events of default. A significant risk factor is the potential for the interest rate to escalate to 18.0% upon default. The loan is short-term in nature, designed to bridge the company until it secures further financing or completes strategic transactions. As a condition to funding, Robert J. Hariri, M.D., entered into a waiver and subordination agreement regarding indebtedness owed to him by the Company.
Key Facts for Investor Verification
- Verify the status of the $1,000,000 loan funding and whether the 30-day maturity has been extended or refinanced.
- Confirm the terms of the subordination agreement with Robert J. Hariri, M.D.
- Monitor the company's progress in securing the "certain financing or other strategic transactions" required to repay the loan at maturity.
- Review the impact of the Board resignation on corporate governance and strategic direction.
- Assess the implications of the related party transaction with the Philip & Daniele Barach Family Trust.